Launch of Nodus Oncology, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on the development of first and best molecules inhibiting new DNA damage response targets

0

Nodus Oncology

NOToncology Iauntsfounded by Cumulus Oncology and in partnership with the Lead Discovery Center, to concentrate on develop first-in-class and best-in-class molecules inhibiting novel DNA damage response targets

  • Newly appointed CEO, Ian Waddell PhD, will lead the discovery and preclinical development of nodes onecology DDR-focused pipeline and will be supported by a team comprising Luis Toledo, PhD, Scientific Founder and Aadvise

Edinburgh, Scotland, September 6, 2022 – Nodus Oncology, a new biotech company focused on developing first and best molecules that inhibit novel DNA damage response (DDR) targets, launches today with seed funding from Cumulus Oncology, a studio of Scottish biotechnology creation, and announces a partnership with the Lead Discovery Center (LDC) in Dortmund (Germany). The funding will be used to expand and grow Nodus’ portfolio of prime and prime assets.

Nodus is led by Chief Executive Dr Ian Waddell PhD, Scientific Director of Cumulus Oncology. With over 30 years of experience leading successful R&D programs as well as broad and deep expertise in oncology, including DDR, Ian brings the expertise needed to successfully develop and deliver the Nodes.

Other key members of the Nodus team include Luis Toledo, PhD, Founder and Scientific Advisor, Nicola Broughton PhD, MBA, Chief Business Officer, Manuelle Debunne PhD, Chief Operating Officer and Scott Doak, Finance Director.

LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in the Nodus pipeline.

The Nodus Oncology pipeline is focused on a number of novel small molecules targeting specific vulnerabilities in the DNA damage response.

Ian WadellCEO of Nodus Oncology said:I am pleased to launch Nodus Oncology today and at lead the company as CEO as we seek to grow the business and its pipeline. Nodus focuses on to develop the next wave of cancer therapies in the DDR space and I look forward to working with colleagues at the LDC to continue the development of differentiated programs against new targets in the DDR area..

Clare Wareing, CEO of Cumulus Oncology says I am delighted to welcome Ian as Node CEO of Oncology. Ian brings with him a wealth of experience in the biopharmaceutical industry focused on the DDR domain and his leadership experience successful drug discovery and development activities will be invaluable as we continue to develop Nodus DDR inhibitor pipeline.

Bert Klebl, CEO of the PMA said: We are delighted to see our collaboration with Cumulus Oncology evolve into a partnership with Nodus Oncology and we look forward to supporting Ian and the Nodus team to expand the of the company RCD pipeline leveraging LDC’s expertise in drug discovery.

For more information about Nodus Oncology, please contact:

Consilium Strategic Communications
Mary-Jane Elliott, Lindsey Neville, Davide Salvi
[email protected]

About Nodus Oncology

Nodus Oncology is a biotechnology company developing first-in-class, best-in-class molecules focused on DNA Damage Response (DDR) in patient subsets where molecular vulnerabilities exist. Founded by Cumulus Oncology, which brings capital and expertise in oncology discovery and development to the creation of new biotechnology companies, Nodus has received seed investment from Cumulus Oncology and other investors. www.nodusoncology.com

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by technology transfer organization Max Planck Innovation, as part of a new approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC supports promising early-stage academic projects and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof of concept in in vivo models as well as candidate nomination. In close collaboration with leading partners from research and industry, the LDC is building a strong and growing portfolio of small molecules and antibodies with exceptional medical and commercial potential. The LDC has a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with AstraZeneca, Apeiron, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Jemincare, Novo Nordisk and Cumulus Oncology. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for business creation. For more information, please visit: https://www.lead-discovery.de/

About Cumulus Oncology

Founded in 2017, Cumulus sources new oncology assets from academic institutes, commercial drug discovery groups and biopharmaceutical companies. The company also identifies new targets for the drug discovery programs it supports and collaborates with. After rigorous due diligence and market valuation activities, negotiations on the terms of the agreement and thorough feasibility of the investment case, the selected assets are transformed into newly created companies. These NewCos are managed at key value inflection points by Cumulus which also takes responsibility for further investing in each NewCo through its network of VC Partners. The founding team is made up of successful life science entrepreneurs, oncologists, scientists and other professionals in oncology drug development and the pharmaceutical industry. Asset classes of interest include small molecules and biologics that target known and novel pathways in cancer, where there is a clear pathway to clinical development, often in molecularly selected subgroups.

For more information, please visit: www.cumulusoncology.com

Share.

Comments are closed.